RCKT (Rocket Pharmaceuticals, Inc. Common Stock)

Insider Trading Activity

Every open-market purchase and sale reported by RCKT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
50
most recent
Open-Market Buys
1
code P
Sales
11
code S
Reporting Insiders
16
current holders
RCKT — Recent Form 4 Transactions (latest 2026-08-20)
FiledInsiderRole TypeSharesValue
2026-08-20 Gaurav Shah CEO Sell
2026-08-20 Martin Wilson General Counsel Sell
2026-08-17 Martin Wilson General Counsel Sell
2026-08-17 Gaurav Shah CEO Sell
2026-08-13 Sarbani Chaudhuri See Remarks Sell
2026-08-13 Christopher James Stevens Chief Operating Officer Sell
2026-08-05 Christopher James Stevens Chief Operating Officer A
2026-08-05 DAVID P SOUTHWELL Director J
2026-07-06 Mikael Dolsten Director A
2026-07-06 Fady Ibraham Malik Director A
2026-07-06 CARSTEN BOESS Director A
2026-07-06 Peter Fong Director A
2026-07-06 DAVID P SOUTHWELL Director A
2026-07-06 RODERICK WONG Director A
2023-02-22 John Militello See Remarks M
2023-02-22 Gaurav Shah CEO Sell
2023-02-22 Gaurav Shah CEO M
2023-02-22 Jonathan David Schwartz See Remarks M
2023-02-22 John Militello See Remarks Sell
2023-02-22 Kinnari Patel See Remarks M
2023-02-22 Jonathan David Schwartz See Remarks Sell
2023-02-16 John Militello See Remarks A
2023-02-16 Jonathan David Schwartz See Remarks A
2023-02-16 Kinnari Patel See Remarks A
2023-02-16 Martin Wilson General Counsel A
2023-02-16 Gaurav Shah CEO A
2022-12-23 RODERICK WONG Director J
2022-12-22 RTW INVESTMENTS, LP Director J
2022-10-11 RODERICK WONG Director Buy
2022-08-16 John Militello See Remarks A
2022-08-16 Martin Wilson General Counsel A
2022-08-16 Kinnari Patel See Remarks A
2022-08-16 Jonathan David Schwartz See Remarks A
2022-06-15 Naveen Yalamanchi Director A
2022-06-15 Fady Ibraham Malik Director A
2022-06-15 DAVID P SOUTHWELL Director A
2022-06-15 Elisabeth Bjork Director A
2022-06-15 Gotham Makker Director A
2022-06-15 RODERICK WONG Director A
2022-06-15 CARSTEN BOESS Director A
2022-06-15 PEDRO P GRANADILLO Director A
2022-04-20 John Militello See Remarks A
2022-04-04 Jonathan David Schwartz See Remarks Sell
2022-04-01 Jonathan David Schwartz See Remarks Sell
2022-03-11 Fady Ibraham Malik Director A
2022-03-09 Gotham Makker Director G
2022-02-16 Carlos Garcia-Parada Chief Financial Officer A
2022-02-16 Jonathan David Schwartz See Remarks A
2022-02-16 Kinnari Patel See Remarks A
2022-02-16 Gaurav Shah CEO A
RCKT — Current Insider Holders
InsiderRole Shares HeldValue
Director 18,263,956
Director 16,272,635
Director 16,185,119
CEO 1,254,935
Director 674,901
General Counsel 673,853
Chief Operating Officer 505,784
Director 317,646
See Remarks 262,809
See Remarks 173,241
See Remarks 94,546
Director 76,195
Director 67,082
Director 52,862
Director 52,862
See Remarks 1,614
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the RCKT quote page; the site-wide leaderboard is on the insider transactions hub.